Cart
×
You are Pioneers Once Again
We are pleased to share the following letter from the CEO of PTC Therapeutics to the Duchenne community. CureDuchenne funded PTC Therapeutics back in 2003 and we are proud […]
CureDuchenne’s Debra Miller and Jak Knowles Spoke on Venture Philanthropy and Duchenne at Recent Conferences
CureDuchenne’s success in venture philanthropy has attracted the attention of the medical research community around the world. Last week, CureDuchenne CEO Debra Miller and Vice President of CureDuchenne Medical and […]
Cardiac Trial for Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
Did you know that heart failure is very common and often fatal in patients with Duchenne muscular dystrophy? The Halt cardiOmyopathy ProgrEssion in Duchenne (HOPE-Duchenne) is a clinical trial […]
Transfer Techniques to Protect Duchenne Patients and Caregivers
Moving someone who has Duchenne from one location to another is no easy task, especially when considering patient and caregiver safety. Jennifer Wallace is a physical therapist who specializes in […]
Speak Up for the Duchenne Community!
After waiting for a very long time, the Duchenne community now has clarity on the Advisory Committee meetings dates for BioMarin and Sarepta. BioMarin’s date is November 24, 2015 […]
Expanding and Improving Duchenne Standard of Care
As a mom of a son with Duchenne, I understand the importance of physical therapy in this disease. Early after Hawken’s diagnosis, we were referred to a physical therapy […]
Welcome Katie Mastro
We are delighted to announce that Katie Mastro has joined joined CureDuchenne as program services manager. She is responsible for managing and expanding the CureDuchenne Cares program, engaging with […]
Researchers Create New Mouse Model for Duchenne with Duplication of Exon 2
Dr. Kevin Flanigan and his team at the Flanigan Lab at Nationwide Children’s Hospital are hard at work researching duplication mutations. They have created a new mouse model for […]
Welcome Dr. Jak Knowles
We couldn’t be prouder that CureDuchenne has played a critical role in the development of what we hope will be the first-ever pharmaceutical treatments for Duchenne muscular dystrophy. Investments by […]